Chemomab TherapeuticsCMMB
13F holders, Q2 2026 (June 30)13holders −2
1new positions
3sold out
1famous investor
$1.62avg. 13F price*
At the end of Q2 2026, 13 institutions reported holding Chemomab Therapeutics Ltd. (CMMB) in their 13F filings, down 2 from Q1 2026. 1 opened new positions and 3 sold out. The largest holders were Citadel Advisors ($154K), ADAR1 Capital Management, LLC ($130K) and Kestra Private Wealth Services, LLC ($100K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Chemomab Therapeutics Ltd.
- CUSIP
- 16385C203
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $23K |
| Exits | 3 | $44K |
All 13F filers, Q1 2026 → Q2 2026: 64,439 shares bought and 36,166 shares sold, net +28,273 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 13 holders
| Citadel Advisors | 0.00% | Add +48.5% | 95,311 | $154K |
| ADAR1 Capital Management, LLC | 0.01% | No change | 80,000 | $130K |
| Kestra Private Wealth Services, LLC | 0.00% | No change | 61,710 | $100K |
| Ikarian Capital, LLC | 0.01% | No change | 51,793 | $84K |
| Rhumbline Advisers | 0.00% | Add +66.2% | 30,529 | $49K |
| XTX Topco Ltd | 0.00% | Reduce -14.2% | 15,987 | $26K |
| Philadelphia Investment Partners, LLC | 0.02% | Add +82.9% | 15,000 | $24K |
| Lido Advisors, LLC | 0.00% | New | 14,341 | $23K |
| BNP Paribas Financial Markets | 0.00% | Reduce -19.2% | 6,805 | $11K |
| GAMMA Investing LLC | 0.00% | Reduce -37.5% | 4,740 | $8K |
| Morgan Stanley | 0.00% | Reduce -21.9% | 3,575 | $6K |
| SBI Securities Co., Ltd. | 0.00% | Add +21.4% | 34 | $55 |
| Caitong International Asset Management Co., Ltd | 0.00% | No change | 8 | $13 |
"% of holder's portfolio" is CMMB's weight in each manager's 13F, not the share of Chemomab Therapeutics Ltd. the manager owns.